Rani Therapeutics Holdings, Inc. Operating Income Loss

• Rani Therapeutics Holdings, Inc. showed an increase of +28.1% in Operating Income Loss from 2024 to 2025.
• This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Rani Therapeutics Holdings, Inc.'s Operating Income Loss has declined by 131.6%.
• Historical annual values: Fiscal year 2025: -$38.31 million | Fiscal year 2024: -$53.31 million | Fiscal year 2023: -$66.10 million | Fiscal year 2022: -$63.45 million | Fiscal year 2021: -$51.60 million | Fiscal year 2020: -$16.54 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026